Standard BioTools to Participate in Upcoming Investor Conferences
26 Julho 2023 - 5:05PM
Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose
– Unleashing tools to accelerate breakthroughs in human health
– today announced Company management will participate in the
following investor conferences:
- Canaccord
Genuity 43rd Annual Growth Conference: Michael Egholm,
PhD, President and Chief Executive Officer, will participate in a
fireside chat on Wednesday, August 9, 2023, at 3:30 p.m. ET.
- UBS
MedTech, Tools and Genomics Summit: Egholm will join in a
panel discussion about emerging life science tools companies on
Wednesday, August 16, 2023, at 7:00 a.m. PT.
Live audio of both webcasts will be available on the Investor
Relations page of the Company’s website at Events &
Presentations. The webcast will be archived and available on
Standard BioTools™ Investor Relations page at
investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), previously known as
Fluidigm Corporation, is driven by a bold purpose – Unleashing
tools to accelerate breakthroughs in human health. Standard
BioTools has an established portfolio of essential, standardized
next-generation technologies that help biomedical researchers
develop medicines faster and better. As a leading solutions
provider, the company provides reliable and repeatable insights in
health and disease using its proprietary mass cytometry and
microfluidics technologies, which help transform scientific
discoveries into better patient outcomes. Standard BioTools works
with leading academic, government, pharmaceutical, biotechnology,
plant and animal research, and clinical laboratories worldwide,
focusing on the most pressing needs in translational and clinical
research, including oncology, immunology, and immunotherapy. Learn
more at standardbio.com or connect with us on Twitter®, Facebook®,
LinkedIn, and YouTube™. Standard BioTools, the Standard BioTools
logo, Fluidigm, the Fluidigm logo, and “Unleashing tools to
accelerate breakthroughs in human health” are trademarks and/or
registered trademarks of Standard BioTools Inc. or its
affiliates in the United States and/or other countries.
All other trademarks are the sole property of their respective
owners. Standard BioTools products are provided
for Research Use Only. Not for use in
diagnostic procedures.
Available Information
Standard BioTools uses its website (standardbio.com),
investor site (investors.standardbio.com), corporate Twitter
account (@Standard_BioT), Facebook page
(facebook.com/StandardBioT), and LinkedIn page
(linkedin.com/company/standard-biotools) as channels of
distribution of information about its products, its planned
financial and other announcements, its attendance at upcoming
investor and industry conferences, and other matters. Such
information may be deemed material information, and Standard
BioTools may use these channels to comply with its disclosure
obligations under Regulation FD. Therefore, investors should
monitor Standard BioTools’ website and its social media accounts in
addition to following its press releases, SEC filings,
public conference calls, and webcasts.
Investor Contacts
Scott R. Greenstone, CFAir@standardbio.com
Peter DeNardo 415 389
6400 ir@standardbio.com
Standard BioTools (NASDAQ:LAB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Standard BioTools (NASDAQ:LAB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024